Document Detail

Cardiac complications associated with trastuzumab in the setting of adjuvant chemotherapy for breast cancer overexpressing human epidermal growth factor receptor type 2 - a prospective study.
MedLine Citation:
PMID:  22661994     Owner:  NLM     Status:  PubMed-not-MEDLINE    
INTRODUCTION: Trastuzumab, a recombinant humanized monoclonal antibody, is targeted against the external domain of the human epidermal growth factor receptor type 2 (HER2). It improves efficacy of HER2-positive breast cancer treatment. The authors present their experience with patients (pts) treated with trastuzumab in the aspects of cardiac complications.
MATERIAL AND METHODS: We observed prospectively 253 women with early positive HER2 breast cancer treated with trastuzumab. Assessment of cardiovascular status, ECG and echocardiography was performed initially and every 3 months until 6(th) month during follow-up.
RESULTS: Cardiac complications developed in 52 pts (20.55%) and included: asymptomatic left ventricle dysfunction (43), symptomatic heart failure (6), new asymptomatic LBBB (1); new negative T-waves in ECG (2). There was a progressive decline in left ventricular ejection fraction (LVEF) during treatment. It was more enhanced in pts with cardiac complications. Following trastuzumab termination/discontinuation LVEF increased but at month 18 still remained significantly lower than initially in both groups (61.07 ±4.84 vs. 59.97 ±5.23 - no cardiac complications; p < 0.05; 58.14 ±4.08% vs. 53.08 ±5.74% - cardiac complications; p < 0.05). During 6-month follow-up 33 out of 46 pts experienced an improvement in left ventricular status. In 13 pts in whom trastuzumab was discontinued, it was restarted; 6 of them successfully completed total therapy. Univariate analysis revealed no association between any cardiovascular risk factor and the development of cardiotoxicity.
CONCLUSIONS: One out of five treated patients discontinues trastuzumab in an adjuvant setting due to cardiac complications. LV dysfunction is the most frequent. Routine cardiac monitoring should be obligatory.
Grzegorz Piotrowski; Rafał Gawor; Arkadiusz Stasiak; Zenon Gawor; Piotr Potemski; Maciej Banach
Related Documents :
10193744 - Transcatheter closure of muscular ventricular septal defects with the amplatzer ventric...
2191784 - Diagnosis of unexpected atrial septal defect by inspired hydrogen appearance time in ad...
8837584 - Morphometric analysis of unbalanced common atrioventricular canal using two-dimensional...
8457394 - Novel uses of the rashkind ductal umbrella in adults and children with congenital heart...
10931804 - Race, sex, poverty, and the medical treatment of acute myocardial infarction in the eld...
12493024 - Changes in the distribution pattern of gelatin-binding protein of 28 kda (adiponectin) ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Archives of medical science : AMS     Volume:  8     ISSN:  1896-9151     ISO Abbreviation:  Arch Med Sci     Publication Date:  2012 May 
Date Detail:
Created Date:  2012-06-04     Completed Date:  2012-10-02     Revised Date:  2013-05-30    
Medline Journal Info:
Nlm Unique ID:  101258257     Medline TA:  Arch Med Sci     Country:  Poland    
Other Details:
Languages:  eng     Pagination:  227-35     Citation Subset:  -    
Department of Cardiology, M. Kopernik Specialist District Hospital, Lodz, Poland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The association of an adenine insertion variant in the 5'UTR of the endothelin-1 gene with hypertens...
Next Document:  Interaction of cerebrovascular disease and contralateral carotid occlusion in prediction of shunt in...